Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) in adults;Pharmakotherapie der aufmerksamkeitsdefizit-/ hyperaktivitätsstörung (ADHS) im erwachsenenalter: Allgemeine grundlagen, epidemiologie, psychopathologie, klassifikation, verlauf, neurobiologie und soziale adaptation

Zeitschrift fur Psychiatrie, Psychologie und Psychotherapie

Volumn 54, Issue 2, 2006, Pages 99-110

  Kordon, Andreas ^a   Fallahpour, Maria Hofecker ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

ADHD in adults; Alternative treatment; Pharmacotherapy; Stimulants

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATOMOXETINE; CLONIDINE; CYTOCHROME P450 2D6; FLUOXETINE; MELPERONE; METHYLPHENIDATE; NEUROLEPTIC AGENT; PEMOLINE; VENLAFAXINE;

ATTENTION DEFICIT DISORDER; BEHAVIOR; COGNITION; COMORBIDITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; EMOTION; HUMAN; PSYCHOTHERAPY; REVIEW;

EID: 33646848576     PISSN: 16614747     EISSN: None     Source Type: Journal    
DOI: 10.1024/1661-4747.54.2.99     Document Type: Review

References (45)

1. Achenbach, T. M., Howell, C. T., McConaughy, S. H. & Stanger, C. (1995). Six-year predictors of problems in a national sample: III. Transitions to young adult syndromes. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 658-669.
2. Arnold, L. E. (1996). Sex differences in ADHD: Conference summary. Journal of Abnormal Child Psychology, 24, 555-569.
3. Barkley, R. A. (1998). ADHD: A handbook for diagnosis and treatment (2nd ed.). New York: Guilford.
4. Barkley, R. A. (2002). Major life activity and health outcome associated with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 63(Suppl. 12), 10-15.
5. Barkley, R. A., Guevremont, D. G., Anastopoulos, A. D., DuPaul, G. J. & Shelton, T. L. (1993). Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: A 3-5 year follow-up survey. Pediatrics, 113, 212-218.
6. Barkley, R. A., Murphy, K. R., O'Connell, T. & Connor, D. F. (2005). Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder. Journal of Safety Research, 36, 121-131.
7. Becker, K. & Wehmeier, P. M. (2003). Atomoxetin zur Behandlung der AHDS. Psychologie und Neurologie, 10, 472-476.
8. Biederman J., Faraone, S. V., Mick, E., Williamson, S., Wilens, T. E., Spencer, T. J., Weber, W., Jetton, J., Kraus, I., Pert, J. & Zallen, B. (1999). Clinical correlates of ADHD in females: Findings from a large group of girls ascertained from pediatric and psychiatric referral sources. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 966-975.
9. Biederman, J., Wilens, T., Mick, E., Spencer, T. & Faraone, S. V. (1999). Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics, 104, e20.
10. Biederman, J., Mick, E., Surman, C., Doyle, R., Hammerness, P., Harpold, T., Dunkel, S., Dougherty, M., Aleardi, M. & Spencer, T. (2005). A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry (Epub ahead of print).
11. Briggs, G. G., Freeman, R. K. & Yaffe, S. J. (2005). Drugs in pregnancy and lactation (7th ed.). Philadelphia: Lippincott Williams & Wilkins.
12. Brown, T. E. (1995). Differential diagnosis of ADD vs. ADHD in adults. In K. G. Nadeau (Ed.), A comprehensive guide to ADD in adults (pp. 93-108). New York: Brunner/Mazel.
13. Cox, D. J., Humphrey, J. W., Merkel, R. L., Penberthy, J. K. & Kovatchev, B. (2004a). Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. Journal of the American Board of Family Practice, 17, 235-239.
14. Cox, D. J., Merkel, R. L., Penberthy, J. K., Kovatchev, B. & Hankin, C. S. (2004b). Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: A pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 269-275.
15. Dodson, W. W. (2005). Pharmacotherapy of adult ADHD. Journal of Clinical Psychology, 61, 589-606.
16. Faraone, S. V. & Wilens, T. (2003). Does stimulant treatment lead to substance use disorder? Journal of Clinical Psychiatry, 64(Suppl. 11), 9-13.
17. Goldman, L. S., Genel, M., Bezman, R. & Slanetz, P. J. (1998). Diagnosis and treatment of attention-deficit/hyperaktive disorder in children and adolescents. Journal of the American Medical Association, 279, 1100-1107.
18. Hart, E. L., Lahey, B. B., Loeber, R., Applegate, B. & Frick, P. J. (1995). Developmental Change in ADHD in boys: A four-year longitudinal study. Journal of Abnormal Child Psychology, 23, 729-749.
19. Hofecker Fallahpour, M., Drewe, J. & Stieglitz, R.-D. (2005). Stimulanzien und Fahrtauglichkeit - wie beeinflusst Methylphenidat das Fahrverhalten? Info Neurologie und Psychiatrie, 6, 16-21.
20. Kollins, S. (2003). Comparing the abuse potential of methylphenidate versus other stimulants: A review of available evidence and relevance to the ADHD patient. Journal of Clinical Psychiatry, 64(Suppl. 11), 14-18.
21. Kordon, A. & Kahl, K. G. (2003). Aufmerksamkeitsdefizit-/ Hyperaktivitätsstörung im Erwachsenenalter. Psychotherapie und Psychologische Medizin, 53, 1-13.
22. Krause, J. & Krause, K.-H. (2005). ADHS im Erwachsenenalter (2. Aufl.). Stuttgart: Schattauer.
23. Kuperman, S., Perry, P. J., Gaffney, G. R., Lund, B. C., Bever-Stille, K. A., Arndt, S., Holman, T. L., Moser, D. J. & Paulsen, J. S. (2001). Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Annals of Clinical Psychiatry, 13, 129-34.
24. Levy, F., Hay, D. A., McStephen, M., Wood, C. & Waldman, I. (1997). ADHD: A category or a continuum? Genetic analysis of a large-scale twin study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 734-744.
25. Lyon, G. R. & Krasnegor, N. A. (Eds.). (1996). Attention, memory, and executive function. Baltimore, MD: Paul H. Books.
26. MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073-1086.
27. MTA Cooperative Group. (2004). National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: 24-month outcomes of treatment strategies for ADHD. Pediatrics, 113, 754-761.
28. Pliszka, S. R. (2005). The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biological Psychiatry, 57, 1385-1390.
29. Pliszka, S. R., McCracken, J. T. & Maas, J. W. (1996). Catecholamines in attention-deficit/hyperactivity disorder: Current perspectives. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 264-272.
30. Schaefer, C. & Spielmann, H. (2001). Arzneiverordnung in Schwangerschaft und Stillzeit (6. Aufl.). München: Urban & Fischer.
31. Schulte-Markwort, M. (2004). Methylphenidat - Zur Geschichte eines Medikaments. In M. Schulte-Markwort & A. Warnke (Hrsg.), Methylphenidat (S. 1-4). Stuttgart: Thieme.
32. Spencer, T., Wilens, T., Biederman, J., Faraone, S. V., Ablon, J. S. & Lapey, K. (1995). A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 52, 434-443.
33. Spencer, T., Biederman, J., Wilens, T., Faraone, S. V., Prince, J., Gerard, K., Doyle, R., Parekh, A., Kagan, J. & Bearman, S. K. (2001). Efficacy of a mixed amphetamin salt compound in adults with attention-deficit/ hyperactivity disorder. Archives of General Psychiatry, 58, 775-782.
34. Spencer, T., Biederman, J., Wilens, T., Doyle, R., Surman, C., Prince, J., Mick, E., Aleardi, M., Herzig, K. & Faraone, S. (2005). A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 57, 456-463.
35. Still, G. G. (1902). Culostian lectures on some abnormal psychical conditions in children. Lancet, i, 1008-1012.
36. Swanson, J. M., Gupta, S., Guinta, D., Flynn, D., Agler, D. & Lerner, M. (1996). Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clinical Pharmacology and Therapeutics, 66, 295-305.
37. Volkow, N. D., Wang, G.-J., Fowler, J. S., Molina, P. E., Logan, J., Galley, S. J., Gifford, A., Ding, Y-S., Wong, C., Pappas, N. R., Zhu, W. & Swanson, J. M. (2003). Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology, 166, 264-270.
38. Volkow, N. D., Wang, G.-J., Fowler, J. S., Telang, F., Maynard, L., Logan, J., Gatley, S. J., Pappas, N., Wong, C., Vaska, P., Zhu, W. & Swanson, J. M. (2004). Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. American Journal of Psychiatry, 161, 1173-1180.
39. Weiss, G., Hechtman, L., Perlman, T., Hopkins, J. & Wener, A. (1979). Hyperactives as young adults: A controlled prospective 10-year follow-up of 75 children. Archives of General Psychiatry, 36, 675-681.
40. Wender, P. H. (1995). Adult attention deficit hyperactivity disorder. Oxford: University Press.
41. Wilens, T. E., Biederman, J., Prince, J., Spencer, T. J., Faraone, S. V., Warburton, R., Schleifer, D., Harding, M., Linehan, C. & Geller, D. (1996). Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. American Journal of Psychiatry, 153, 1147-1153.
42. Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R., Prince, J., Polisner, D., Solhkhah, R., Comeau, S., Monuteaux, M. C. & Parekh, A. (2001). A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. American Journal of Psychiatry, 158, 282-288.
43. Wilens, T. E., Faraone, S. V., Biederman, J. & Gunawardene, S. (2003). Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 111, 179-185.
44. Wilens, T. E., Haight, B. R., Horrigan, J. P., Hudziak, J. J., Rosenthal, N. E., Connor, D. F., Hampton, K. D., Richard, N. E. & Modell, J. G. (2005a). Bupropion XL in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled study. Biological Psychiatry, 57, 793-801.
45. Wilens, T. E., Hammerness, P. G., Biederman, J., Kwon, A., Spencer, T. J., Clark, S., Scott, M., Podolski, A., Ditterline, J. W., Morris, M. C. & Moore, H. (2005b). Blood pressure changes associated witz medication treatment of adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 66, 253-259.